IL20 and breast carcinoma: Anti-IL–20 monoclonal antibody (mAb) 7E decreased osteolytic bone lesions in mouse models of breast cancer and protected ovariectomized mice against osteoporotic bone loss, both of which support the notion that IL–20 is critical for regulating of tumor-mediated osteolysis.